focus -WSS

focus

author：Wikipedia 2025-10-02 14:38:46 - browse：26841

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Why health care costs have stayed mostly flat since 2010

hotspot

WSS

Europe sees delivery challenges ahead on Alzheimer's therapies

Eli Lilly to acquire Versanis in heated race for weight loss drugs

SEC charges former device maker CEO with $41 million fraud

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Can CDC director Mandy Cohen drive consensus in Washington?

The new HIV moral panic

explore

focus

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Dobbs anniversary: the lost opportunity of abortion as health care

Prime Medicine, Myeloid Therapeutics clash over genome

Trump demands the U.S. pay no more for drugs than other countries … again

How to keep neuroscience’s past racism from being its future

After affirmative action ruling, medical educators look to 'holistic review'

Medicare drug price negotiation hasn't dried up venture capital

Peter Hotez and the public health issue of online harassment

Can CDC director Mandy Cohen drive consensus in Washington?

Wikipedia

Keeping primary care docs in field isn't impossible, says AAFP CEO

Involuntary treatment for addiction doesn't work

Care demand spikes challenge UnitedHealth’s provider arm

Why police arrested suspected Gilgo Beach killer away from his house

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

focus

hotspot

entertainment

explore